Ligand Pharmaceuticals’ lung cancer drug, Targretin, didn’t meet endpoints of improved overall survival in two Phase III studies.
WebProWorld
Ligand Pharmaceuticals’ lung cancer drug, Targretin, didn’t meet endpoints of improved overall survival in two Phase III studies.